• News
  • SAN DIEGO
  • BioTech

FDA accepts NDA submission for carbamazepine IV

Ligand Pharmaceuticals Inc.'s Captisol licensee Lundbeck LLC announced that the FDA has accepted for review a new drug application for its investigational therapy intravenous carbamazepine.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11119 N. Torrey Pines Rd. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
94.81
  0.56  
+ 0.59%
291,577,000
112.4
41.99

Insider Trade Data

Date Insider Shares Type Value
08/17/2015 Knott, David M 4,000 Sell $383,937
08/17/2015 Knott, David M 4,000 Sell $383,937
08/13/2015 Knott, David M 50,000 Sell $4,813,782
08/07/2015 Knott, David M 200 Sell $19,803
08/06/2015 Davis, Todd C 19,670 Exchange $232,288

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!